ADPT Stock Analysis: Buy, Sell, or Hold?
ADPT - Adaptive Biotechnologies Corporation Common Stock
$12.81
0.39 (3.18%)
▲
5d:
-6.26%
30d:
-20.07%
90d:
-23.32%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When ADPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADPT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ADPT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ADPT is currently trading at $12.80, which is considered oversold relative to its 30-day fair value range of $13.46 to $15.99.
Technical Outlook: Technically, ADPT is in a strong uptrend. The price is currently testing key support at $12.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.86 (+68.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADPT is in a strong uptrend. The price is currently testing key support at $12.97. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.86 (+68.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$13.46 -
$15.99
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 68.1% below Wall St target ($20.86)
- CAUTION: Recommendation downgraded due to -6.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$13.46 -
$15.99
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$12.97
Resistance Level
$14.51
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-45.96
Wall Street Target
$20.86
(+68.1%)
Revenue Growth (YoY)
51.0%
Profit Margin
-21.5%
Share & Embed Analysis
Last updated: March 30, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Julie Rubinstein
SELL
19060 shares
2026-03-18
Julie Rubinstein
SELL
19060 shares
2026-03-16
Julie Rubinstein
SELL
19060 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
